New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options

Rhea-AI Summary

Penumbra announced new data showing that patients with intermediate-risk pulmonary embolism (PE) treated with their computer assisted vacuum thrombectomy (CAVT) technology experienced better outcomes compared to other treatments. The study, presented at VIVA 2024, analyzed 2,060 adult patients and revealed that CAVT resulted in 25-35% shorter hospital stays, 25-30% higher rates of home discharge, and 2-3 times fewer complications. The technology also demonstrated potential financial benefits, with hospitals potentially seeing up to a 75% gain in profitable contribution margin if 10% more patients are treated with CAVT compared to anticoagulation alone.

Positive

• 25-35% reduction in hospital length of stay
• 25-30% higher rate of patients discharged home
• 2-3 times fewer complications compared to other treatments
• 75% potential gain in profitable contribution margin for hospitals
• Comparable in-hospital mortality rates to other treatment options

Negative

• None.

• Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference
• Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system

ALAMEDA, Calif., Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT™) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options. Additionally, in-hospital mortality was low with CAVT, with no significant difference between treatment options. The late-breaking study was presented this week at the Vascular Interventional Advances (VIVA) 2024 Conference.

"This first-of-a-kind analysis demonstrates that patients treated with CAVT utilized fewer hospital resources," said Parag J. Patel, M.D., M.S., FSIR, who presented the data and is an interventional radiologist at Froedtert Hospital in Milwaukee, WI. "These findings, as well as recent studies which show CAVT's positive impact on patient outcomes, strongly showcase the significant benefits of CAVT over other treatment options for PE. We will continue to see the growing adoption of CAVT as a frontline therapy given the notable beneficial impact on patients and the overall health system."

The retrospective study utilized the Vizient Clinical Data Base to identify 2,060 adult (³18 years) inpatients with intermediate-risk PE. This rigorous 1:1 propensity score matched analysis included resource use and health outcomes among patients in the U.S. treated with Penumbra's Lightning™ Flash™ or Lightning 12 technology compared to patients in the U.S. treated with anticoagulation, catheter directed thrombolysis or other mechanical thrombectomy devices.

When compared to other modalities studied, the data showed that CAVT resulted in:

• 25-35 percent shorter total hospital length of stay
• 25-30 percent higher average rate of patients discharged home
• 2-3 times fewer average composite complications

"CAVT will continue to redefine the way physicians treat symptomatic PE. We have a growing body of evidence that demonstrates the meaningful benefits of CAVT on patient outcomes," said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. "Now with this study, the findings suggest that by increasing patient access to advanced therapies like CAVT, it can also have an important, positive impact on hospital systems by greatly reducing resource utilization versus other modalities, therefore decreasing the overall cost to the healthcare system."

In the study, CAVT was associated with improvement in contribution margin relative to anticoagulation alone. An example given was that if 10 percent more patients are treated with CAVT, hospitals could see up to a 75 percent gain in profitable contribution margin, representing thousands of dollars more per patient compared to treatment with anticoagulation alone. This data was presented separately in a symposium during the VIVA 2024 Conference.

Penumbra's Lightning Flash portfolio is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus. It features Penumbra's Lightning CAVT technology with the latest dual clot detection algorithms, using both pressure and flow-based processes to detect blood clot and blood flow. The Lightning Flash™ and Lightning Flash™ 2.0 catheters are made with MaxID hypotube technology, allowing an inner diameter similar to large-bore catheters while maintaining a lower profile and a soft, atraumatic tip design. They are designed to help remove blood clots with speed, safety and simplicity, allowing physicians to better navigate the body's complex anatomy and deliver high power aspiration for clot removal.

About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

Important Safety Information
Additional information about Penumbra's products can be located on Penumbra's website at https://www.penumbrainc.com/providers. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use. Risk information can be found at http://www.peninc.info/risk.

Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 22, 2024. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Contact
Jennifer Heth		Parinaz Farzin
Penumbra, Inc.		Merryman Communications
jheth@penumbrainc.com		parinaz@merrymancommunications.com
510-995-9791		310.600.6746

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-late-breaking-data-show-patients-treated-with-penumbras-computer-assisted-vacuum-thrombectomy-technology-for-pulmonary-embolism-experience-shorter-hospital-stays-and-fewer-complications-compared-to-other-treatment-options-302296321.html

SOURCE Penumbra, Inc.

FAQ

What are the key benefits of Penumbra's CAVT technology for PE treatment?

Penumbra's CAVT technology shows 25-35% shorter hospital stays, 25-30% higher home discharge rates, and 2-3 times fewer complications compared to other treatments for pulmonary embolism.

How does Penumbra's CAVT technology impact hospital finances?

Hospitals could see up to a 75% gain in profitable contribution margin if 10% more patients are treated with CAVT compared to anticoagulation alone.

What were the main findings of the CAVT study presented at VIVA 2024?

The study of 2,060 adult patients showed CAVT resulted in shorter hospital stays, higher home discharge rates, fewer complications, and improved hospital contribution margins compared to other treatments.